Melanoma;Melanoma

Medicine (Spain)

Volumn 11, Issue 26, 2013, Pages 1597-1607

  Villalobos Leon M L ^a   Molina Villaverde, R ^a   Lopez Gonzalez J L ^a   Alvarez Mon Soto M ^a  

^a not available

Author keywords

Chemotherapy; Inmunotherapy; Ipilimumab; Melanoma; Vemurafenib

Indexed keywords

B RAF KINASE; IPILIMUMAB; RECOMBINANT INTERFERON; VEMURAFENIB;

ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISTANT METASTASIS; DRUG MEGADOSE; GENE MUTATION; IMMUNOTHERAPY; MELANOMA; PRACTICE GUIDELINE; SENTINEL LYMPH NODE BIOPSY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84875302216     PISSN: 03045412     EISSN: 15788822     Source Type: Journal    
DOI: 10.1016/S0304-5412(13)70511-0     Document Type: Article

References (40)

1. J. Ferlay, ShinHR, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008 Int J Cancer 46 2010 2893 2917
2. S. Sáenz, J. Conejo-Mir, and A. Cayuela Melanoma epidemiology in Spain Actas Dermosifiliogr 96 7 2005 411 418 (Pubitemid 41512523)
3. E. Regidor, and J.L. Gutiérrez-Fisac Patrones de mortalidad en España, 2009 2012 Ministerio de Sanidad, Servicios Sociales e Igualdad Madrid
4. S.B. Gruber, and B.K. Armstrong Cutaneous and ocular melanoma D. Schottenfeld, J.F. Fraumeni Jr. Cancer Epidemiology and Prevention 3th edition 2006 Oxford University Press New York 1196 1229
5. C. de Torre, and J.M. Ródenas Factores de riesgo. Melanoma familiar J. Martínez, A. Piñero, C. de Torre, J.M. Ródenas, Melanoma cutáneo. Guía de Práctica Clínica 2012 Consejería de Sanidad y Política Social. Servicio Murciano de Salud Murcia
6. M.A. Reginster, C. Pierard-Franchimont, G.E. Piérard, and P. Quatresooz Molecular dermatopathology in malignant melanoma Dermatol Res Pract 2012 2012 684032
7. C. Jhappan, F.P. Noonan, and G. Merlino Ultraviolet radiation and cutaneous malignant melanoma Oncogene 22 2003 3099 3112 (Pubitemid 36713762)
8. College of American pathologist-CAP Reference Resources and Publications. Disponible en: http://www.cap.org/apps/docs/committees/cancer/cancer-protocols/ 2011/SkinMelanoma-11protocol-feb.pdf. Consultado marzo de 2012.
9. A. Breslow Tumor thickness level of invasion and node dissection in stage I cutaneous melanoma Ann Surg 182 1975 572 575
10. W.H. Clark Jr., L. From, E.A. Bernardino, and M.C. Mihm The histogenesis and biological behavior of primary human malignant melanoma of the skin Cancer Res 29 3 1969 705 727
11. M. Heenen, and M. Laporte Molecular markers associated to prognosis of melanoma Ann Dermatol Venereol 130 11 2003 1025 1031 (Pubitemid 37548696)
12. V.C. Gray-Schopfer, S. da Rocha Dias, and R. Marais The role of B-RAF in melanoma Cancer Metastasis Rev 24 1 2005 165 183 [published correction appears in Cancer Metastasis Rev. 2005;24(2):367].
13. A.J. Miller, and M.C. Mihm Jr. Melanoma N Engl J Med 355 1 2006 51 65
14. K. Wolff, R.A. Johnson, and D. Suurmond Fitzpatrick. Atlas en color y sinopsis de dermatología clínica 5 ed. 2005 McGraw-Hill- Interamericana Madrid 302 335
15. P.I. Haigh, L.A. DiFronzo, and D.R. McCready Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis Can J Surg 46 6 2003 419 426 (Pubitemid 38315579)
16. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, and D.R. Byrd Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 2009 6199 6206
17. M. Yancovitz, N. Finelt, M.A. Warycha, P.J. Christos, M. Mazumdar, and R.L. Shapiro Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma Cancer 110 2007 1107 1114 (Pubitemid 47312877)
18. E. Maubec, J. Lumbroso, F. Masson, V. Suciu, F. Kolb, and G. Mamelle F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm Melanoma Res 17 3 2007 147 154 (Pubitemid 46788099)
19. S.P. Bagaria, M.B. Faries, and D.L. Morton Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute J Surg Oncol 101 2010 669 676
20. E.T. Creagan, R.J. Dalton, D.L. Ahmann, S.H. Jung, R.F. Morton, and R.M. Langdon Jr. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 11 1995 2776 2783
21. A. Hauschild, M. Weichenthal, K. Rass, R. Linse, C. Berking, and J. Böttier Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial J Clin Oncol 28 5 2010 841 846
22. S. Agarwala, S.J. Lee, and L.E. Flaherty Randomized phase III trial of high-dose interferon alfa-2b for 4 weeks induction only in patients with intermediate-and high-risk melanoma 2011 ASCO Annual Meeting 2011 Abstract 8505. Presented June 4
23. K. Wheatley, N. Ives, B. Hancock, M. Gore, A. Eggermont, and S. Suciu Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit?. A meta-analysis of the randomised trials Cancer Treat Rev 29 4 2003 241 252 (Pubitemid 37069655)
24. D. Pirard, M. Heenen, C. Melot, and P. Vereecken Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis Dermatology 208 1 2004 43 48 (Pubitemid 38142333)
25. S. Mocellin, S. Pasquali, C.R. Rossi, and D. Nitti Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J Natl Cancer Inst 102 7 2010 493 501
26. R. Dummer, A. Hauschild, M. Guggenheim, L. Jost, and G. Pentheroudakis Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl5 2010 v194 v197
27. National Comprehensive Cancer Network Guidelines. Disponible en: http://www.nccn.org.
28. D. Moreno-Ramírez, L. de la Cruz Merino, L. Ferrandiz, R. Villegas-Portero, and A. Nieto-Garcia Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety Oncologist 15 2010 416 427
29. T.F. Wood, L.A. DiFronzo, D.M. Rose, P.I. Haigh, S.L. Stern, and L. Wanek Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 8 2001 658 662 (Pubitemid 32847931)
30. D.W. Ollila, E.C. Hsueh, S.L. Stern, and D.L. Morton Metastasectomy for recurrent stage IV melanoma J Surg Oncol 71 1999 209 213 (Pubitemid 29388015)
31. S. Agrawal, J.M. Kane, B.A. Guadagnolo, W.G. Kraybill, and M.T. Ballo The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma Cancer 115 2009 5836 5844
32. C.M. Balch, S.J. Soong, J.E. Gershenwald, J.F. Thompson, D.S. Reintgen, and N. Cascinelli Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 19 2001 3622 3634 (Pubitemid 32786275)
33. C. Kim, C.W. Lee, L. Kovacic, A. Shah, R. Klasa, and K.J. Savage Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide Oncologist 15 7 2010 765 771
34. M.R. Middleton, J.J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, and S. Seiter Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 1 2000 158 166 (Pubitemid 30036349)
35. M.F. Avril, S. Aamdal, J.J. Grob, A. Hauschild, P. Mohr, and J.J. Bonerandi Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study J Clin Oncol 22 6 2004 1118 1125 (Pubitemid 41095046)
36. C. Zimpfer-Rechner, U. Hofmann, R. Figl, J.C. Becker, U. Trefzer, and I. Keller Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG) Melanoma Res 13 5 2003 531 536 (Pubitemid 37266956)
37. M.B. Atkins, M.T. Lotze, J.P. Dutcher, R.I. Fisher, G. Weiss, and K. Margolin High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 7 1999 2105 2116 (Pubitemid 29318842)
38. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
39. C. Robert, L. Thomas, I. Bondarenko, S.M.D.J.W. O'Day, and C. Garbe Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 26 2011 2517 2526
40. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, and P. Ascierto Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516